Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:12:55 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:XNCR - XENCOR INC - https://www.xencor.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
XNCR - Q1.08.73·9.231.08.97-0.10-1.1417.43,5463,9739.20  9.36  8.9527.24  7.1616:33:04May 0715 min RT 2¢

Recent Trades - Last 10 of 3973
Time ETExPriceChangeVolume
16:33:04Q8.97-0.1019,796
16:09:42Q8.97-0.108
16:04:11Q8.97-0.101
16:04:10Q8.97-0.101
16:04:05Q8.97-0.101
16:04:01Q8.97-0.101
16:02:29Q8.97-0.101,665
16:02:29Q8.97-0.1019
16:02:29Q8.97-0.10486
16:01:49Q8.97-0.10188

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-05-07 16:01U:XNCRNews ReleaseXencor Reports First Quarter 2025 Financial Results
2025-04-29 16:01U:XNCRNews ReleaseXencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
2025-03-13 16:01U:XNCRNews ReleaseXencor Appoints Todd Simpson to Board of Directors
2025-02-27 08:01U:XNCRNews ReleaseXencor Reports Fourth Quarter and Full Year 2024 Financial Results
2024-11-26 16:01U:XNCRNews ReleaseXencor to Participate at Upcoming Investor Conferences
2024-11-06 16:01U:XNCRNews ReleaseXencor Reports Third Quarter 2024 Financial Results
2024-11-04 07:00U:XNCRNews ReleaseXencor Doses First Subject in Phase 1/2 Study of XmAb(TM)942 in Development for Patients with Inflammatory Bowel Disease
2024-10-10 08:09U:XNCRNews ReleaseXencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
2024-10-04 08:01U:XNCRNews ReleaseXencor Announces Upcoming Change to Board of Directors
2024-09-12 16:01U:XNCRNews ReleaseXencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
2024-09-11 06:31U:XNCRNews ReleaseXencor Announces Pricing of $175 Million Public Offering of Common Stock
2024-09-10 16:01U:XNCRNews ReleaseXencor Announces Proposed Public Offering of Common Stock
2024-09-09 07:31U:XNCRNews ReleaseXencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
2024-09-06 08:01U:XNCRNews ReleaseXencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
2024-08-05 16:01U:XNCRNews ReleaseXencor Reports Second Quarter 2024 Financial Results